Gain Therapeutics, Inc.
GANX
$1.71
-$0.04-2.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 13.92% | 1.03% | 8.34% | 3.83% | 2.08% |
| Total Depreciation and Amortization | 1.88% | 1.06% | -1.33% | 17.31% | 16.98% |
| Total Amortization of Deferred Charges | 0.00% | -2.13% | 2.17% | 5.62% | 10.34% |
| Total Other Non-Cash Items | 19.83% | 26.81% | -11.90% | -29.03% | 0.20% |
| Change in Net Operating Assets | -3,652.39% | -433.35% | -344.32% | -185.30% | -97.36% |
| Cash from Operations | 2.73% | -4.79% | -0.04% | -23.20% | -15.44% |
| Capital Expenditure | 95.95% | -420.93% | -46.41% | 12.96% | 72.66% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.42% | -82.21% | -51.16% | 13.05% | 88.84% |
| Cash from Investing | -100.43% | -82.41% | -51.31% | 13.14% | 91.33% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.33% | 0.11% | -2.13% | -3.07% | -4.88% |
| Issuance of Common Stock | -59.52% | 29.11% | 5.13% | 555.55% | 567.43% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 100.00% | -- | -- | -- |
| Cash from Financing | -59.23% | 32.42% | 2.93% | 562.26% | 574.42% |
| Foreign Exchange rate Adjustments | 399.34% | 235.14% | -207.97% | 88.84% | -133.65% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -196.43% | -133.74% | -131.46% | 217.78% | 232.97% |